Cognitive disorders in mice: cytokine signaling pathways as therapeutic targets.
Surplus accumulation of regulatory T cells (Tregs) is known to be at the bottom of many morbid conditions, among them being neuropsychiatric diseases. In particular, Tregs may inhibit Th1 cells, including brain autoimmune lymphocytes, controlling the local microglial response and brain tissue homeostasis. The present study was undertaken in an attempt to suggest a novel approach for the treatment of maladaptation to mental stress associated with excessive Treg accumulation. Recently it was shown that alkylating drugs (ADs), such as melphalan and cyclophosphamide (Cy) in the dose 100-fold lower than cytostatic one are capable to disturb signal transduction by IL-2R. In this study we demonstrated that IL-2R is not a unique receptor, which may be blocked with ADs. Similar effect has been shown for two other surface receptors: TNFR and Fas. Molecular mechanisms of the receptor blockage were investigated on the model of TNF signaling. Study of NF-κB activity in nuclear extracts showed that alkylating agents act at the level of surface receptor or of the receptor platform. It was also shown that ADs administration in ultralow doses results in selective elimination of Tregs. In this study we used a new laboratory model of Treg accumulation in mice. Such Treg accumulation was associated with cognitive and behavioral abnormalities, which may be prevented by Cy administration.
Research Centre for Medical Genetics, Moscow, Russia. osugariver@yahoo.com
Alexander
A
Pukhalsky
Galina
G
Shmarina
Vladimir
V
Alioshkin
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000276:immunology*; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008558:Melphalan / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects* / Q000276:immunology*; D013315:Stress, Psychological / Q000188:drug therapy* / Q000503:physiopathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D018906:Antineoplastic Agents, Alkylating; D016207:Cytokines; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D015375:Receptors, Interleukin-2; D003520:Cyclophosphamide; D008558:Melphalan